A study in breast cancer survivors receiving cyclophosphamide-based therapy by Su et al. evaluated time to chemotherapy-related ovarian failure and the effect of five SNPs in CYP3A4, CYP2B6, and CYP3A5. This evidence concerns the gene CYP3A4 and ovarian dysfunction.